KR20150065881A - 암 표적화 치료 및 암 재발 예방을 위한 헤모글로빈 기반 산소운반체 함유 약학적 조성물 - Google Patents

암 표적화 치료 및 암 재발 예방을 위한 헤모글로빈 기반 산소운반체 함유 약학적 조성물 Download PDF

Info

Publication number
KR20150065881A
KR20150065881A KR1020157012185A KR20157012185A KR20150065881A KR 20150065881 A KR20150065881 A KR 20150065881A KR 1020157012185 A KR1020157012185 A KR 1020157012185A KR 20157012185 A KR20157012185 A KR 20157012185A KR 20150065881 A KR20150065881 A KR 20150065881A
Authority
KR
South Korea
Prior art keywords
hemoglobin
tumor
cells
based oxygen
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157012185A
Other languages
English (en)
Korean (ko)
Inventor
빙 로우 웡
노만 펑 맨 와이
수이 이 쿽
수이 이 ?
스제 항 라우
Original Assignee
비전 글로벌 홀딩스 리미티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비전 글로벌 홀딩스 리미티드. filed Critical 비전 글로벌 홀딩스 리미티드.
Publication of KR20150065881A publication Critical patent/KR20150065881A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A61K47/48—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020157012185A 2012-10-12 2013-10-11 암 표적화 치료 및 암 재발 예방을 위한 헤모글로빈 기반 산소운반체 함유 약학적 조성물 Ceased KR20150065881A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261712853P 2012-10-12 2012-10-12
US61/712,853 2012-10-12
US13/713,031 2012-12-13
US13/713,031 US20140106004A1 (en) 2012-10-12 2012-12-13 Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
PCT/US2013/064418 WO2014059199A1 (en) 2012-10-12 2013-10-11 Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence

Publications (1)

Publication Number Publication Date
KR20150065881A true KR20150065881A (ko) 2015-06-15

Family

ID=50475529

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157012185A Ceased KR20150065881A (ko) 2012-10-12 2013-10-11 암 표적화 치료 및 암 재발 예방을 위한 헤모글로빈 기반 산소운반체 함유 약학적 조성물

Country Status (21)

Country Link
US (2) US20140106004A1 (https=)
EP (1) EP2906222A4 (https=)
JP (1) JP6113850B2 (https=)
KR (1) KR20150065881A (https=)
CN (1) CN104717966B (https=)
AP (1) AP2015008315A0 (https=)
AR (1) AR093023A1 (https=)
AU (1) AU2013329121B2 (https=)
BR (1) BR112015007475A2 (https=)
CA (1) CA2884521C (https=)
CL (1) CL2015000897A1 (https=)
EA (1) EA201500301A1 (https=)
IL (1) IL237763A (https=)
MA (1) MA37994A2 (https=)
MX (1) MX367562B (https=)
PH (1) PH12015500562B1 (https=)
SG (3) SG10201608747RA (https=)
TW (1) TW201414489A (https=)
UY (1) UY35082A (https=)
WO (1) WO2014059199A1 (https=)
ZA (1) ZA201501949B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230141306A (ko) 2022-03-31 2023-10-10 충남대학교산학협력단 저산소증 완화능을 갖는 페길화 헤모글로빈 나노클러스터를 포함하는 항암 화학-광역학 치료용 조성물

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9636404B2 (en) * 2013-05-13 2017-05-02 Vision Global Holdings Ltd. Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging
CN106536056B (zh) 2014-06-13 2021-07-16 儿童医学中心公司 分离线粒体的产品和方法
US9814759B2 (en) * 2014-07-02 2017-11-14 Cheer Global Ltd. Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
US11903974B2 (en) 2015-11-30 2024-02-20 Flagship Pioneering Innovations V, Inc. Methods and compositions relating to chondrisomes from cultured cells
WO2017124037A1 (en) * 2016-01-15 2017-07-20 The Children's Medical Center Corporation Therapeutic use of mitochondria and combined mitochondrial agents
CA3028589A1 (en) * 2016-06-21 2017-12-28 Therapure Biopharma Inc. Hemoglobin-targeted drug delivery for the treatment of cancer
US11197872B2 (en) 2017-04-21 2021-12-14 Lunella Biotech, Inc. Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs)
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
CA3063450A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
PH12019502594A1 (en) 2017-05-19 2020-10-26 Lunella Biotech Inc Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
KR102854338B1 (ko) 2017-06-26 2025-09-03 루넬라 바이오테크 인코포레이티드 미토케토신: 암 세포에서 케톤 대사를 표적화하는 미토콘드리아-기반의 치료제
JPWO2019124423A1 (ja) * 2017-12-19 2020-10-22 国立大学法人 岡山大学 がんの進行抑制、治療、予防及び／又は再発予防剤
CN111558032B (zh) * 2020-05-19 2023-08-22 中国科学院宁波材料技术与工程研究所 一种蛋白纳米药物及其制备方法与应用
CN114344263B (zh) * 2022-02-21 2023-08-01 杭州普略生物科技有限公司 一种用于靶向巨噬细胞增强肿瘤治疗效果的纳米蛋白胶束及其制备方法和应用
WO2025222059A1 (en) * 2024-04-17 2025-10-23 Prolong Pharmaceuticals Llc Method of treating cancer using pegylated bovine hemoglobin
CN119746044A (zh) * 2025-03-06 2025-04-04 润方（北京）生物医药研究院有限公司 血红蛋白氧载体在制备抗病毒药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478806A (en) * 1989-11-22 1995-12-26 Enzon, Inc. Enhancement of antitumor therapy with hemoglobin-based conjugates
CA2236344A1 (en) * 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
US20050164915A1 (en) * 2002-04-01 2005-07-28 Sangart, Inc. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
JP2006508939A (ja) * 2002-10-29 2006-03-16 エンジーン， インコーポレイテッド 癌処置のための組成物
EP2389068A4 (en) * 2009-01-23 2012-07-18 Cancer Rec Tech Ltd HEMGE OF THE HEDGEHOG SIGNAL PATH
NO2440239T3 (https=) * 2009-06-09 2018-02-10
EP2451459B1 (en) * 2009-07-07 2017-11-22 Normoxys, Inc. Method of reducing multi-drug resistance using inositol tripyrophosphate
US8808748B2 (en) * 2010-04-20 2014-08-19 Vindico NanoBio Technology Inc. Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same
US7989593B1 (en) * 2010-05-27 2011-08-02 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
US20110319332A1 (en) * 2010-06-23 2011-12-29 Bing Lou Wong Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
US8048856B1 (en) * 2010-06-23 2011-11-01 Billion King, Ltd. Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
US7932356B1 (en) * 2010-06-23 2011-04-26 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230141306A (ko) 2022-03-31 2023-10-10 충남대학교산학협력단 저산소증 완화능을 갖는 페길화 헤모글로빈 나노클러스터를 포함하는 항암 화학-광역학 치료용 조성물

Also Published As

Publication number Publication date
JP2015534946A (ja) 2015-12-07
AU2013329121A1 (en) 2015-04-09
PH12015500562A1 (en) 2015-05-04
US9056098B2 (en) 2015-06-16
ZA201501949B (en) 2016-01-27
SG11201502133SA (en) 2015-04-29
BR112015007475A2 (pt) 2017-08-08
US20140106004A1 (en) 2014-04-17
SG10201608747RA (en) 2016-12-29
JP6113850B2 (ja) 2017-04-12
WO2014059199A8 (en) 2014-05-30
IL237763A (en) 2017-07-31
CN104717966A (zh) 2015-06-17
CA2884521C (en) 2018-05-01
MX2015004512A (es) 2015-12-01
EA201500301A1 (ru) 2015-08-31
EP2906222A4 (en) 2016-06-22
MX367562B (es) 2019-08-27
PH12015500562B1 (en) 2015-05-04
TW201414489A (zh) 2014-04-16
HK1206281A1 (en) 2016-01-08
EP2906222A1 (en) 2015-08-19
SG10201607846PA (en) 2016-11-29
CA2884521A1 (en) 2014-04-17
US20140303085A1 (en) 2014-10-09
CL2015000897A1 (es) 2015-08-21
UY35082A (es) 2014-07-31
MA37994A2 (fr) 2016-06-30
AR093023A1 (es) 2015-05-13
AU2013329121B2 (en) 2017-05-25
AP2015008315A0 (en) 2015-03-31
CN104717966B (zh) 2018-08-24
WO2014059199A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
KR20150065881A (ko) 암 표적화 치료 및 암 재발 예방을 위한 헤모글로빈 기반 산소운반체 함유 약학적 조성물
Grover et al. Myeloid-derived suppressor cells: a propitious road to clinic
EP2679221B1 (en) Method to enhance tissue regeneration
El-Beshlawy et al. Recent trends in treatment of thalassemia
ES2913073T3 (es) Direccionamiento del sistema inmunitario innato para inducir tolerancia a largo plazo y resolver la acumulación de macrófagos en aterosclerosis
US8431117B2 (en) Sickled erythrocytes with anti-tumor agents induce tumor vaso-occlusion and tumoricidal effects
Bartnicki et al. The influence of the pleiotropic action of erythropoietin and its derivatives on nephroprotection
JPWO2018021200A1 (ja) Ｒｕｎｘ阻害剤
JP6100252B2 (ja) 異なる治療用途のための熱安定性酸素キャリアを含有する医薬組成物
Menger et al. Erythropoietin accelerates the revascularization of transplanted pancreatic islets
Luo et al. Genetically engineered biomimetic nanoparticles for synergistic activation of glioma-associated macrophages against glioblastoma
Garcia-Manero et al. Research and clinical updates on IRAK4 and its roles in inflammation and malignancy: themes and highlights from the 1st symposium on IRAK4 in cancer
JP2018035112A (ja) 抗癌剤の抗腫瘍効果の増強剤、癌治療剤、及び癌治療用医薬組成物。
US12059429B2 (en) Hornerin: a novel non-VEGF mediated angiogenic protein expressed in both human and mouse angiogenic endothelial cells and human pancreatic cancer cells
Sasajima et al. Transplanting normal vascular proangiogenic cells to tumor-bearing mice triggers vascular remodeling and reduces hypoxia in tumors
AU2024208037B2 (en) Medicinal products and methods for the alleviation of cancer immunotherapy-associated cytokine release syndrome
HK1206281B (en) Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
Li et al. Triple-remodeling of tumor microenvironment through hyaluronidase-assisted folate-targeted lipid nanoparticle-mediated siVEGF/siPD-L1 for enhanced tumor immunotherapy
US20180230466A1 (en) Methods for treating tumors
CA3279458C (en) Medicinal products and methods for the alleviation of cancer immunotherapy-associated cytokine release syndrome
Kuang et al. TRIM21 Exacerbates Ischemic Brain Injury by Promoting Astrocyte-Mediated Neuroinflammation via K63-Linked Ubiquitination of MDA5
Bian et al. Nanobiotechnological basis of an
Miyauchi The Role of Neuropilin 1 in Glioma Associated Microglia and Macrophages
Kiriakidis et al. Role of angiogenesis in the pathogenesis of arthritis: Potential therapeutic applications
HK1193037B (en) Method to enhance tissue regeneration

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150508

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170601

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20170601

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170703

Patent event code: PE09021S01D

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20171108

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180326

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20171108

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20170703

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20180326

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20171228

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20170829

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20170601

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20180607

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180524

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20180326

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20171228

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20171108

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170829

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20170703

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170601